share_log

HC Wainwright & Co. Reiterates Buy on Aptose Biosciences, Maintains $7 Price Target

Benzinga ·  Jun 14 23:03

HC Wainwright & Co. analyst Joseph Pantginis reiterates Aptose Biosciences (NASDAQ:APTO) with a Buy and maintains $7 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment